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Focal necrosisAbstract Purpose: To assess effects of levetiracetam (LEV) within its therapeutic range at a
54 mg/day and 1/4 LD50 = 70 mg/kg body weight for white albino male and female rats weighing
an average of 180 ± 60 g has been studied in order to demonstrate whether LEV would affect the
internal organs at the histological level.
Methods: Animals were randomly separated into control (n= 20), study group I (n= 20) and
study group II (n= 20). They were obtained from the animal house, Assuit University. They were
maintained in environmentally controlled rooms at a temperature of 28–32 C, 40–60% humidity,
in a noise free environment. Oral administration of 54 mg/day and 70 mg/kg LEV for groups I and
II, respectively, was given while physiologic saline (0.045 ml) was given to the control group.
Results: Microscopic evaluation of the intestine, kidney, suprarenal glands and spleen, revealed
that there was no statistical difference between the treated and control groups. Four specimens
of the liver out of 20 (20%), showed focal necrosis around central veins. Lung sections that were
obtained from 15 out of 20 (75.0%) rats in the study group II showed various histopathological
ﬁndings compared to those of the control group. These ﬁndings include thickening of interstitial
septa, interstitial ﬁbrosis, chronic inﬂammatory inﬁltration of cells, and congestion of blood vessels.
Conclusions: LEV is considered as a safe drug in its therapeutic dose. Its safety needs further stud-
ies with long term follow-up.
ª 2015 The International Association of Law and Forensic Sciences (IALFS). Production and hosting by
Elsevier B.V. All rights reserved.Introduction
Levetiracetam (LEV) is a novel antiepileptic drug (AED)
which was discovered in the early 1980s. In 1999 the FDAapproved LEV monotherapy for the management of partial
onset seizures. It has greatly increased the treatment options
available to patients with generalized epilepsies1 and refractory
epilepsy.2
LEV {(S)-a-ethyl-2-oxo-pyrrolidine acetamide} is an ana-
log of piracetam.3 It is rapidly and completely absorbed after
oral administration and it is predominantly eliminated as an
unchanged drug in the urine. Its metabolism is independent
of the cytochrome P450 enzyme system. LEV has not beenll rights
42 H.A.M. Omer, M.A.M. Kutbdemonstrated to interact with other drugs in either direction.4,5
Clearance of LEV is signiﬁcantly reduced in patients with sev-
ere hepatic impairment and concomitant renal impairment
(hepatorenal syndrome).6
LEV appears to act at the synaptic site by binding with the
vesicle protein 2A (SV2A), and has a restraining effect on the
secretion of neurotransmitters in the presynaptic area.7,8 It
inhibits secretion of calcium from neuronal stores and activa-
tion of neurons without interfering with normal activation.
Additionally, it has been shown that LEV does not involve
inhibitory and excitatory neuro-transmission.9
Materials and methods
A total number of sixty adult male and female albino rats
weighing 180–220 g, were obtained from the animal house,
Assuit University. They were maintained in environmentally
controlled rooms at a temperature of 28–32 C, 40–60%
humidity, in a noise free environment and 12 h light–dark
cycle. The female and male albino rats were kept in different
spacious cages. All the rats had access to water and animal diet
and libitum.
The animals were classiﬁed in three groups:
Control group: consisted of 20 (10 male and 10 female rats)
with normal saline administration.A
Figure 1 (A) Photomicrograph of the liver section in a animal treat
(thin arrow), focal necrotic area (thick arrow) partial distortion of the
liver section in a animal treated with LEV in dose of 1/4 LD50 showin
A B
Figure 2 (A and B) Photomicrographs of lung sections in animals tre
congestion with chronic inﬂammatory cell inﬁltration which destroyed t
E) (X100).Group 1: consisted of 20 (10 male and 10 female rats) with
therapeutic dose of LEV oral administration of
54 mg/day,10 in two divided doses per day.
Group II: consisted of 20 (10 male and 10 female rats) with
a high dose of LEV oral administration of 1/4
LD50 = 70 mg/kg body weight,
11 in two divided doses per
day.
LEV was given in its already prepared formulation
(Tiratam) an oral solution of 100 mg/ml from Al-Andalous
for Pharmaceuticals-Egypt Industries. In all animals drugs
were given orally by a gastric tube.
After sixty days of the experimental period each rat was
killed by cervical dislocation, and the internal organs were
obtained for histopathological study. Organs were preserved
in 10% buffered neutral formalin. They were dehydrated and
embedded in parafﬁn. Serial section 5 lm thick were cut and
stained with hematoxylin and eosin (H and E). Observations
were made by examining the serial section under light
microscope.
Results
Microscopic examination, using H and E of LEV treated
groups (therapeutic dose and 1/4 LD50) related histopatholog-
ical changes in the intestine, kidney, spleen and suprarenalB
ed with LEV in dose of 1/4 LD50 showing central vein congestion
liver architecture (H and E) (X200). (B) Photomicrograph of the
g dilated congested portal vein (arrow) (H and E) (X100).
ated with LEV in a dose of 1/4 LD50 showing vascular dilation and
he wall of a secondary bronchus. (A) (H and E) (X200), (B) (H and
Figure 4 Photomicrograph of the lung section in a animal
treated with LEV in a dose of 1/4 LD50 showing chronic
inﬂammatory cell inﬁltration (H and E) (X400).
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the control group.
No signiﬁcant difference was found in the histological
examination of liver sections in the tissue of animals treated
with LEV 54 mg/day (Group I) as compared to those of con-
trols while in the dose of 70 mg/day (1/4 LD50) there were hep-
atic lesions. The most prominent microscopic changes
consisted of centrilobular congestion in 70% and focal necrosis
around the central vein 20% (Fig. 1A), dilated and congested
portal veins 70% (Fig. 1B).
Light microscopic examination, using H and E, revealed
that the study Group I exhibited no histopathological differ-
ence in comparison to the control group, while various histo-
logical ﬁndings were presented in lung sections obtained
from the study group II (75.0%). These ﬁndings include: con-
gestion of the blood vessels 85% (Fig. 2A and B) &
(Fig. 3A, B and E). A thickened interalveolar (interstitial)
septum and ﬁbrosis was found in (90%) (Fig. 2A–D) and
chronic inﬂammatory cell inﬁltration (90%), particularly
around secondary bronchi and interstitial septa which may
reduce the alveolar spaces for gaseous exchange (Figs. 2–4)
(see Table 1).
Discussion
LEV-induced histopathological changes in internal organs
(kidney, intestine, spleen and suprarenal glands) have not been
reported. The present study evaluated the effect of LEV on the
internal organs of the albino rats. Chronic administration of
LEV at a therapeutic dose showed no histopathologicalA B
C D
Figure 3 (A and B) Photomicrographs of lung sections in animals tre
congestion with chronic inﬂammatory cell inﬁltration and thickening o
some alveolar spaces. (H and E) (X100). (C and D) Photomicrographs
showing high power of thickened alveolar septum (H and E) (X400).
LEV in a dose of 1/4 LD50 showing vascular dilation and congestion (differences as compared to those of control. Similar data are
mentioned in a clinical study of Incecik et al., who suggest that
the therapeutic dose of LEV does not alter liver functions.12
Our study showed that the hepatocellular and lung lesions
occurred in those treated with a higher dose of LEV (group II).
Congestion of central veins, focal necrosis, and dilated and
congested portal veins were detected in the liver sections of
group II. Despite extensive uses of LEV there are no veriﬁed
reports describing the possible histopathological side-effects,
especially the hepatotoxic reactions. Overstreet et al. demon-
strated that hepatocyte necrosis was found in those treated
with lamotrigine.13 Meshkibaf et al. mentioned that a higher
dose of gabapentin caused scattered necrotic foci in liverE
ated with LEV in a dose of 1/4 LD50 showing vascular dilation and
f interalveolar septum and interstitial ﬁbrosis with obliteration of
of lung sections in animals treated with LEV in a dose of 1/4 LD50
(E) Photomicrograph of the lung section in a animal treated with
H and E) (X100).
Table 1 Histopathological ﬁndings in a high-dose group II (20 animals).
Histopathological lesions Severity of lesions
Mild (+) Moderate (++) Severe (+++)
Male Female Male Female Male Female
No % No % No % No % No % No %
Liver
Centrilobular congestion (14 animals) 0 0.0 0 0.0 2 14.3 0 0.0 4 28.6 8 57.1
Focal necrosis around central vein (4 animals) 0 0.0 0 0.0 0 0.0 0 0.0 3 75.0 1 25.0
Dilated and congested portal veins (14 animals) 0 0.0 0 0.0 0 0.0 0 0.0 6 42.9 8 57.1
Lung
Congestion of the blood vessels (17 animals) 0 0.0 0 0.0 1 5.9 2 11.8 9 52.9 5 29.4
Thickened interalveolar septum and ﬁbrosis (18 animals) 0 0.0 0 0.0 0 0.0 0 0.0 11 61.1 7 38.9
Chronic inﬂammatory cell inﬁltration (18 animals) 0 0.0 0 0.0 0 0.0 0 0.0 9 50.0 9 50.0
44 H.A.M. Omer, M.A.M. Kutbparenchymal cells.14 Saraswathy et al. reported that
phenytoin-treated animals exhibited severe congestion, peri-
portal inﬂammation, centrilobular congestion, fatty degenera-
tion and hepatocellular necrosis.15
The mechanism of LEV-induced liver injury remains
unknown. It is suggested that there may be underlying
immunoallergic, genetic, toxic or acquired mitochondrial
abnormalities as a major determinant to hepatotoxicity.
Reactive metabolites from AED can in some cases, lead to
direct cytotoxicity and liver cell necrosis, whereas in other
cases this may lead to new antigen formation inducing
immunoallergic mechanisms.16,17
The present results have demonstrated that a high dose of
LEV causes histopathological changes in rat lungs.
Congestion of the blood vessels, thickened interalveolar (inter-
stitial) septum and ﬁbrosis and chronic inﬂammatory cell inﬁl-
tration were observed. These ﬁndings are in agreement with
the study by Newsome et al.16 who stated that LEV was impli-
cated in the pathogenesis of interstitial pneumonitis suggesting
that long term use of LEV could precipitate a diffuse intersti-
tial pneumonitis-like reaction.18 Saravanan et al. demonstrated
that increased AED drug concentrations of lamotrigine trig-
gered a diffuse interstitial process of relatively recent onset,
with features consistent with diffuse lung disease.19
In agreement with our study is Travis et al. who reported
that nonspeciﬁc interstitial pneumonia, lymphocytic interstitial
pneumonia, or even patchy alveolar septal lymphoplasmacytic
inﬁltrates without appreciable airway disease or parenchymal
scarring are the most common pulmonary morphologic pat-
terns that are associated with anticonvulsants and other agent
toxicities.20 Furthermore, Nikaido et al. and El Khayat et al.
concluded that many antiepileptic drugs induced interstitial
pneumonia and disturbed pulmonary functions for epileptic
patients on regular prolonged use and they demonstrated that
drug-induced interstitial lung disease should be considered as a
possible complication of anticonvulsant treatment.21,22
The precise mechanism by which LEV exerts its lung injury
with long-term use is unknown. Other anticonvulsant drugs
such as carbamazepine appeared to be more injurious on lung
parenchyma. A number of reports have highlighted pulmonary
immune-mediated hypersensitivity to carbamazepine. Suchhypersensitivity may involve type 3 immune complex and type
4 delayed hypersensitivity reaction.23,24
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